TNFRSF17 and Miyoshi myopathy: Severe ICANS (grades 3–4 according to NCI-CTC grading scales) may occur in up to 31% of patients receiving anti-CD19 CAR T cells and 9 % of patients with MM receiving anti-BCMA CAR T-cell therapy (3).